Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc at William Blair Growth Stock Conference Transcript

Jun 06, 2023 / 09:00PM GMT
Release Date Price: €28.8 (-1.37%)
Tim Lugo
William Blair & Company - Analyst

Good afternoon. For those of you who I haven't met, I'm Tim Lugo, the head of biotech and pharma research here at William Blair. And this is going to be a little different than our usual presentation and breakout. We're just going to do a fireside chat, and I'm joined with Mark Foley, CEO of Revance Therapeutics. We'll get into what Revance does to give everyone a nice overview.

In general, though, I view the company is bringing innovation to the aesthetics world. They are a leader in marketing DAXXIFY, obviously, recently approved as well as fillers and a fintech platform. It's a very exciting company, and it's a great time to look at the company and to do some work on them as I think they're in the very early stages of what should be a nice long growth cycle in aesthetics, but also therapeutics as well towards the end of the summer. So, we'll get into all of that.

But with that, maybe Mark, we can just start with the -- and I must say please check out williamblair.com for all relevant disclosures. Our compliance officer does not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot